3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
Specimen Handling
4
lutetium Lu 177 dotatate
3
gallium Ga 68 dotatate
3
Magnetic Resonance Spectroscopy
3
olaparib
2
cabozantinib
2
belzutifan
2
Temozolomide
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
6-fluorodopamine
2
3-Iodobenzylguanidine
2
tipifarnib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pegfilgrastim
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
atezolizumab
1
Stem Cell Transplantation
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Interleukin-13
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
lanreotide
×
1 year
×
Clear all
NCT03946527
2026-03-02
LAMPARA
Columbia University
Phase 2
Active not recruiting
10 enrolled